
Zeynep Irem Ozay/X
Mar 22, 2025, 13:05
Zeynep Irem Ozay: Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US
Zeynep Irem Ozay, Postdoctoral Research Fellow at Huntsman Cancer Institute, shared an article she and her colleagues authored on X:
“Just in JAMA Network Open.
Real world Treatment data from >8500 patients with mRCC kidney cancer.
After 2018, only 38% and 14% of patients received 2nd and 3rd line treatment respectively.
Thanks to my mentors.”
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US
Authors: Zeynep Irem Ozay et al.
Benjamin L Maughan
cancer
Chadi Hage Chehade
Clear cell renal cell carcinoma (ccRCC)
Ethan Anderson
Georges Gebrael
Gliceida Galarza Fortuna
Metastatic Clear Cell Renal Cell Carcinoma
Micah Ostrowski
Miguel Zugman
Neeraj Agarwal
Nicolas Sayegh
OncoDaily
Oncology
Salvador Jaime-Casas
Sumanta K. Pal
Umang Swami
Vinay Mathew Thomas
Yeonjung Jo
Zeynep Irem Ozay
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 22, 2025, 12:47
Mar 22, 2025, 12:27
Mar 22, 2025, 12:06
Mar 22, 2025, 10:56
Mar 22, 2025, 10:52
Mar 22, 2025, 10:49
Mar 22, 2025, 10:34